RED HERRING PROSPECTUS Dated: July 10, 2023 Please read Section 26 and 32 of the Companies Act, 2013
(This Red Herring Prospectus will be updated upon filing with the RoC)
100% Book Built Issue
(Please scan this QR Code to view the RHP)
Asarfi Hospital Limited | |||
CIN: U85110JH2005PLC011673 | |||
REGISTERED OFFICE | CONTACT PERSON | EMAIL AND TELEPHONE | |
Baramuri, Bishunpur Polytechnic, Dhanbad- | Seepika | Gupta, Company | E-mail: cs@asarfihospital.com |
828130 Jharkhand | Secretary & Compliance Officer | Tel No: +91 96088 33708 | |
PROMOTERS OF THE COMPANY
Harendra Singh, Nayan Prakash Singh, Udai Pratap Singh, Madhuri Singh and Nitu Singh
WEBSITE
www.asarfi.in
DETAILS OF THE ISSUE
TYPE | FRESH ISSUE | OFS SIZE | TOTAL | ELIGIBILITY | |
SIZE | (BY NO. OF SHARES OR | ISSUE SIZE | |||
(IN ₹ LAKHS) | BY AMOUNT IN ₹) | ||||
Fresh | ₹ [•] Lakhs | Nil | ₹ [•] Lakhs | THIS ISSUE IS BEING MADE IN TERMS | OF |
Issue | REGULATION 229 AND 253(1) OF CHAPTER IX OF THE | ||||
SEBI (ICDR) REGULATIONS, 2018 AS AMENDED. | |||||
DETAILS OF OFFER FOR SALE, SELLING SHAREHOLDERS AND THEIR AVERAGE COST OF ACQUISITION - | NOT | ||||
APPLICABLE AS THE ENTIRE ISSUE CONSTITUTES FRESH ISSUE OF EQUITY SHARES | |||||
RISK IN RELATION TO THE FIRST ISSUE | |||||
The face value of the Equity Shares is ₹10 each. The Floor Price, Cap Price and Issue Price determined by our Company, in consultation with the Book Running Lead Manager, on the basis of the assessment of market demand for the Equity Shares by way of the Book Building Process, as stated under "Basis for Issue Price" on page 90 should not be considered to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.
GENERAL RISKS
Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or a dequacy of the Red Herring Prospectus. Specific attention of the investors is invited to the section "Risk Factors" beginning on page 25 of this Red Herring Prospectus.
ISSUER'S ABSOLUTE RESPONSIBILITY
Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Red Herring Prospectus contains all information with regard to our Company and the Issue, which is material in the context of the Issue, that the information contained in this Red Herring Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Red Herring Prospectus as a whole or any of such information or the expression of any such opinions or intentions, misleading in any material respect.
LISTING
The Equity Shares Issued through this Red Herring Prospectus are proposed to be listed on the SME Platform of BSE Limited (" BSE SME" ). In terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018 as amended from time to time, our Company has received "in-principle" approval letter dated July 07, 2023 from BSE Limited ("BSE") for using its name in the Offer Document for listing of our shares on the SME Platform of BSE. For the purpose of this Issue, the Designated Stock Exchange will be the BSE Limited ("BSE").
BOOK RUNNING LEAD MANAGER TO THE ISSUE
Name and Logo | Contact Person | |
HEM SECURITIES LIMITED | Akun Goyal | |
REGISTRAR TO THE ISSUE |
Email & Telephone
Email: ib@hemsecurities.comTel. No.: +91- 22- 49060000
Name and Logo
CAMEO CORPORATE SERVICES LIMITED
Contact Person
K. Sreepriya
Email & Telephone
Email: priya@cameoindia.com
Tel No:+91-44-40020700
ISSUE PROGRAMME
ANCHOR INVESTOR BID/ISSUE PERIOD*: FRIDAY, JULY 14, 2023
BID/ISSUE OPENS ON: MONDAY, JULY 17, 2023
BID/ISSUE CLOSES ON:
WEDNESDAY, JULY 19, 2023
*The Company may, in consultation with the Book Running Lead Manager, consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/Issue Period shall be one Working Day prior to the Bid/Issue Opening Date.
RED HERRING PROSPECTUS 100% Book Built Issue Dated: July 10, 2023
Please read Section 26 and 32 of the Companies Act, 2013
Asarfi Hospital Limited
CIN: U85110JH2005PLC011673
Our Company was originally incorporated as a private limited Company under the name of "Asarfi Hospita l Private Limited" on October 04, 2005 under the pr ovisions of the Companies Act, 1956 with the Registrar of Companies, Bihar & Jharkhand, bearing registration number as 011673. Thereafter, our Company was converted from private limited to public limited, pursuant to special resolution passed by the shareholders of the Company at the Extraordinary general meeting held on January 03, 2012 and the name of our Company was changed from "Asarfi Hospital Private Limited" to "Asarfi Hospital Limited" vide fresh certificate of incorporation dated February 08, 2012 issued by the Registrar of Companies, Jharkhand.
Registered Office: Baramuri, Bishunpur Polytechnic, Dhanbad, Jharkhand - 828130, India
Contact Person: Seepika Gupta, Company Secretary & Compliance Officer
Tel No: +91 96088 33708; E-mail: cs@asarfihospital.com; Website: www.asarfi.in
Promoters of our Company: Harendra Singh, Nayan Prakash Singh, Udai Pratap Singh, Madhuri Singh and Nitu Singh
DETAILS OF THE ISSUE
INITIAL PUBLIC OFFER OF UPTO 51,80,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF ASARFI HOSPITAL
LIMITED ("OUR COMPANY" OR "AHL" OR "THE ISSUER") AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹[●] LAKHS ("PUBLIC ISSUE") OUT OF WHICH 2,60,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER
RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 49,20,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ [●] LAKHS IS HEREIN AFTER REFERRED
TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISS UE WILL CONSTITUTE 26.33% AND 25.00% RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.
THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BRLM AND WILL BE ADVERTISED IN ALL EDITION OF BUSINESS STANDARD (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER) AND ALL EDITION OF BUSINESS STANDARD (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER, AND DHANBAD EDITION OF RANCHI EXPRESS, A REGIONAL NEWSPAPER (THE REGIONAL LANGUAGE OF DHANBAD WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE SME PLATFORM OF BSE ("BSE SME") FOR T HE PURPOSES OF UPLOADING ON THEIR WEBSITE
In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of three Working Days, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank.
The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50 % of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that o ur Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Port ion"), of which one-third shall be reserved for dom estic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RIBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 242 of this Red Herring Prospectus.
The face value of the Equity Shares is ₹ 10 each. The Floor Price, Cap Price and Issue Price determined by our Company, in consultation with the Book Running Lead Manager, on the basis of the assessment of market demand for the Equity Shares by way of the Book Building Process, as stated under "Basis for Issue Price" on page 90 should not be considered to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.
GENERAL RISKS
Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), no r does SEBI guarantee the accuracy or adequacy of the Red Herring Prospectus. Specific attention of the investors is invited to the section "Risk Factors" beginning on page 25 of this Red Herring Prospectus.
ISSUER'S ABSOLUTE RESPONSIBILITY
The Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Red Herring Prospectus contains all information with regard to the Company and the Issue, which is material in the context of the Issue, that the information contained in this Red Herring Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Red Herring Prospectus as a whole or any of such information or the expression of any such opinions or intentions, misleading in any material respect.
LISTING
The Equity Shares Issued through this Red Herring Prospectus are proposed to be listed on the SME Platform of BSE Limited ("BSE SME"). In terms of the Ch apter IX of the SEBI (ICDR) Regulations, 2018 as amended from time to time, our Company has received "in-principle" approva l letter dated July 07, 2023 from BSE Limited ("BSE ") for using its name in the Offer Document for listing of our shares on the SME Platform of BSE. For the purpose of this Issue, the Designated Stock Exchange will be the BSE Limited ("BSE").
BOOK RUNNING LEAD MANAGER TO THE ISSUE | REGISTRAR TO THE ISSUE |
HEM SECURITIES LIMITED | CAMEO CORPORATE SERVICES LIMITED |
904, A Wing, Naman Midtown, Senapati Bapat Marg, | |
Address: No.1 Club House Road Chennai-600002 Tamil Nadu, India. | |
Elphinstone Road, Lower Parel, Mumbai-400013, India | |
Tel No.: +91-44-40020700 | |
Tel. No.: +91- 022- 49060000; Fax No.: +91- 022- 22625991 | |
Email: priya@cameoindia.com | |
Email: ib@hemsecurities.com | |
Investor Grievance Email: investor@cameoindia.com | |
Investor Grievance Email: redressal@hemsecurities.com | |
Contact Person: K. Sreepriya Vice President & Company Secretary | |
Website: www.hemsecurities.com | |
Website: www.cameoindia.com | |
Contact Person: Mr. Akun Goyal | |
SEBI Registration Number: INR000003753 | |
SEBI Registration Number. INM000010981 | |
ISSUE PROGRAMME |
ANCHOR INVESTOR BID/ ISSUE PERIOD*:
FRIDAY, JULY 14, 2023
BID/ISSUE OPENS ON: MONDAY, JULY 17, 2023
BID/ISSUE CLOSES ON:
WEDNESDAY, JULY 19, 2023
*The Company may, in consultation with the Book Running Lead Manager, consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/Issue Period shall be one Working Day prior to the Bid/Issue Opening Date.
TABLE OF CONTENTS
SECTION | CONTENTS |
- GENERAL
DEFINITIONS AND ABBREVIATIONS
CERTAIN CONVENTIONS, USE OF FINANCIAL INFORMATION AND MARKET DATA AND CURRENCY OF FINANCIAL PRESENTATION
FORWARD LOOKING STATEMENTS
- SUMMARY OF RED HERRING PROSPECTUS
- RISK FACTORS
IV. | INTRODUCTION |
THE ISSUE | |
SUMMARY OF OUR FINANCIALS | |
GENERAL INFORMATION | |
CAPITAL STRUCTURE | |
OBJECTS OF THE ISSUE | |
BASIS FOR ISSUE PRICE | |
STATEMENT OF POSSIBLE TAX BENEFITS |
- ABOUT THE COMPANY INDUSTRY OVERVIEW OUR BUSINESS
KEY INDUSTRY REGULATIONS AND POLICIES HISTORY AND CORPORATE STRUCTURE OUR MANAGEMENT
OUR PROMOTERS & PROMOTER GROUP DIVIDEND POLICY
VI. | FINANCIAL INFORMATION OF THE COMPANY |
RESTATED FINANCIAL STATEMENTS | |
OTHER FINANCIAL INFORMATION | |
STATEMENT OF FINANCIAL INDEBTEDNESS | |
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND | |
RESULTS OF OPERATIONS | |
CAPITALISATION STATEMENT | |
VII. | LEGAL AND OTHER INFORMATION |
OUTSTANDING LITIGATIONS AND MATERIAL DEVELOPMENTS | |
GOVERNMENT AND OTHER APPROVALS | |
OUR GROUP COMPANY | |
OTHER REGULATORY AND STATUTORY DISCLOSURES | |
VIII. | ISSUE RELATED INFORMATION |
TERMS OF THE ISSUE | |
ISSUE STRUCTURE | |
ISSUE PROCEDURE | |
RESTRICTIONS ON FOREIGN OWNERSHIP OF INDIAN SECURITIES | |
IX. | MAIN PROVISIONS OF THE ARTICLES OF ASSOCIATION OF OUR COMPANY |
- OTHER INFORMATION
MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION DECLARATION
PAGE NO
16
18
19
25
46
48
51
60
81
90
95
97
109
127
138
142
154
160
161
192
193
195
202
203
212
219
221
231
238
242
267
269
282
283
Asarfi Hospital Limited
SECTION I - GENERAL
DEFINITIONS AND ABBREVIATIONS
This Red Herring Prospectus uses certain definitions and abbreviations which, unless the context otherwise indicates or implies, shall have the meaning as provided below. References to any legislation, act, regulation, rule, guideline or policy shall be to such legislation, act, regulation, rule, guideline or policy, as amended, supplemented or re-enacted from time to time, and any reference to a statutory provision shall include any subordinate legislation made from time to time under that provision.
The words and expressions used in this Red Herring Prospectus but not defined herein, shall have, to the extent applicable, the meaning ascribed to such terms under the Companies Act, 2013, the SEBI (ICDR) Regulations, 2018, the Securities Contracts Regulation Act, 1956 ("SCRA"), the Depositories Act or the rules and regulations made there under.
Notwithstanding the foregoing, terms used in of the sections "Statement of Possible Tax Benefits", "Financial In formation of the Company" and "Main Provisions of the Articles of Association" on page 95, 161 and 269 respectively, shall have the meaning ascribed to such terms in such sections.
General Terms
Terms
- AHL" , " the Company" , " our Company", "Issuer" and "Asarfi Hospital Limited"
- we" , " us" and " our"
- you" , " your" or " yours"
Description
Asarfi Hospital Limited, a Company incorporated in India under the Companies Act, 1956, having its Registered office at Baramuri, Bishunpur Polytechnic, Dhanbad-828130, Jharkhand.
Unless the context otherwise indicates or implies refers to our Company. Prospective investors in this Issue
Company related and Conventional terms
Term
AOA/ Articles/ Articles of Association
Audit Committee
Auditors/ Statutory Auditors
Bankers to our Company
Board of Directors/ the Board/ our Board
Chief Financial Officer/ CFO Companies Act/ Act
Company Secretary and
Compliance Officer
Depositories
Depositories Act Director(s) / our Directors DP/ Depository Participant
DP ID
EquityShareholders/ Shareholders
Equity Shares
Fugitive economic offender
Independent Director
ISIN
Description
Articles of Association of our Company, as amended, from time to time
The Committee of the Board of Directors constituted as the Company's Audit Committee in accordance with Section 177 of the Companies Act, 2013 as described in the chapter titled "Our Management" beginning on page 142 of this Red Herring Prospectus.
The Statutory Auditors of our Company being M/s. D. N. Dokania & Associates, (Firm Registration No. as 050042C).
HDFC Bank Limited
The Board of Directors of our Company, including all duly constituted Committees thereof. For further details of our Directors, please refer to section titled "Our Management" beginning on page 142 of this Red Herring Prospectus.
The Chief Financial Officer of our Company being Harendra Singh
The Companies Act, 2013 and amendments thereto and erstwhile Companies Act 1956 as applicable
The Company Secretary & Compliance Officer of our Company being Seepika Gupta (M. No.: A37984)
National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL).
The Depositories Act, 1996, as amended from time to time.
The Director(s) of our Company, unless otherwise specified
A depository participant as defined under the Depositories Act
Depository's Participant's Identity Number
Persons/ Entities holding Equity Shares of our Company
Equity Shares of the Company of Face Value of ₹ 10/- each unless otherwise specified in the context thereof.
Shall mean an individual who is declared a fugitive economic offender under section 12 of the Fugitive Economic Offenders Act, 2018 (17 of 2018)
An Independent Director as defined under Section 2(47) of the Companies Act, 2013 and as defined under the Listing Regulations. For details of our Independent Directors, see "Our Management" on page 142 of this Red Herring Prospectus.
International Securities Identification Number. In this case being INE0DN001027
1
Asarfi Hospital Limited
Term
Key Management Personnel/
KMP
MOA/Memorandum/ Memorandum of Association MD or Managing Director Materiality Policy
Nomination and Remuneration Committee
Non-Executive Director NRIs / Non-Resident Indians
Promoter(s)
Promoter Group
Person or Persons
RBI Act
Registered Office of our Company
Reserve Bank of India/ RBI
Restated Financial Information/
Statements
RoC/ Registrar of Companies
SEBI
SEBI Act
SEBI AIF Regulations
SEBI FII Regulations
SEBI FPI Regulations
SEBI FVCI Regulations
SEBI Insider Trading Regulations
SEBI SBEB Regulations
SEBI Listing Regulations, 2015/
SEBI Listing Regulations/
Listing Regulations/ SEBI (LODR)
Description
Key Management Personnel of our Company in terms of Regulation 2(1)(bb) of the SEBI Regulations and the Companies Act, 2013. For details, see section titled "Our Management" on page 142 of this Red Herring Prospectus.
Memorandum of Association of Asarfi Hospital Limited as amended from time to time.
The Managing Director of our Company, Udai Pratap Singh
The policy adopted by our Board on February 13, 2023 for identification of Group Company, material outstanding litigation and material outstanding dues to creditors, pursuant to the disclosure requirements under the SEBI (ICDR) Regulations, 2018 as amended from time to time.
The nomination and remuneration committee of our Board constituted in accordance with Section 178 of the Companies Act, 2013 as described in the chapter titled "Our Management" beginning on page 142 of this Red Herring Prospectus
A Director not being an Executive Director, in our case, Sukanti Kumar Das
A person resident outside India, as defined under Foreign Exchange Management Act , 1999 and who is a citizen of India or a Person of Indian Origin under Foreign Exchange Management (Transfer or Issue of Security by a Person Resident Outside India) Regulations, 2000.
Shall mean promoters of our Company i.e. Harendra Singh, Nayan Prakash Singh, Udai Pratap Singh, Madhuri Singh and Nitu Singh. For further details, please refer to section titled "Our Promoter & Promoter Group" beginning on page 154 of this Red Herring Prospectus. Includes such Persons and companies constituting our Promoter Group covered under Regulation 2(1) (pp) of the SEBI (ICDR) Regulations, 2018 as enlisted in the section "Our Promoter and Promoter Group" beginning on page 154 of this Red Herring Prospectus.
Any individual, sole proprietorship, unincorporated association, unincorporated organization, body corporate, corporation, company, partnership, limited liability company, joint venture, or trust or any other entity or organization validly constituted and/or incorporated in the jurisdiction in which it exists and operates, as the context requires.
The Reserve Bank of India Act, 1934 as amended from time to time.
The Registered Office of our Company situated at Baramuri, Bishunpur Polytechnic, Dhanbad-828130 Jharkhand India.
Reserve Bank of India constituted under the RBI Act.
The Restated Financial statements of our Company comprising of the Restated Statement of Assets and Liabilities as at March 31, 2023, March 31, 2022 and March 31, 2021 and the Restated Profit & Loss Account and Restated Cash Flows for the period ended March 31, 2023, March 31, 2022 and March 31, 2021 of our Company prepared in accordance with Indian GAAP and the Companies Act and restated in accordance with the SEBI (ICDR) Regulations, 2018 and the Revised Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the ICAI, together with the schedules, notes and annexure thereto. Unless specified otherwise refers to ROC Jharkhand situated at Ministry Of Corporate Affairs, Mangal Tower, 4th Floor, Old Hazaribagh Road, Near Kanta Toli Chowk, Ranchi- 834001, Jharkhand.
Securities and Exchange Board of India constituted under the SEBI Act, 1992. Securities and Exchange Board of India Act, 1992, as amended
Securities and Exchange Board of India (Alternate Investments Funds) Regulations, 2012, as amended.
Securities and Exchange Board of India (Foreign Institutional Investors) Regulations, 1995, as amended from time to time.
Securities and Exchange Board of India (Foreign Portfolio Investors) Regulations, 2014, as amended from time to time.
Securities and Exchange Board of India (Foreign Venture Capital Investor) Regulations, 2000, as amended from time to time.
The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended, including instructions, notifications and clarifications issued by SEBI from time to time.
Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014. The Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended, including instructions and clarifications issued by SEBI from time to time.
2
Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Asarfi Hospital Ltd. published this content on 05 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 October 2023 06:46:06 UTC.